IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational ...

Earnings Estimate Revisions for IGC Pharma, Inc. This company is expected to earn -$0.11 per share for the fiscal year ending March 2025, which represents a year-over-year change of 50%.

The International Grains Council (IGC) cut its 2023-24 global corn crop forecast, reflecting reduced production potential in the U.S. due to drought conditions. IGC forecasts global corn ...

IGC Industries, operating in the Textiles - General sector and classified as a Smallcap on the BSE, currently has its share price at ₹6.15. The stock has experienced fluctuations today, with a ...

IGC Pharma has reported encouraging interim results from its ongoing Phase II CALMA trial (NCT05543681) of IGC-AD1, an investigational treatment for agitation in dementia related to Alzheimer’s ...

Ram Mukunda, CEO commented, "We're pleased to see this strong vote of confidence from our new advisors. Their strategic investment underscores their belief in IGC Pharma's mission to transform the ...

POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a ...

POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a ...